Eversion raised €2.3M in a Seed round announced on July 30, 2026. Eversion wants to offer people with musculoskeletal complaints a data-based, transparent and sustainable solution.
Eversion wants to offer people with musculoskeletal complaints a data-based, transparent and sustainable solution.
Eversion, based in Konstanz, Germany, announced €2.3M in Seed financing on July 30, 2026.
Participants include Kammerer Holding, Kreissparkasse Biberach.
The company develops AI-powered software and data infrastructure to make robots used in factories work more efficiently.
Alchemab Therapeutics is developing natural protective antibodies designed to keep people free of hard-to-treat diseases.